Money
Filter News
Found 55,536 articles
-
On Oct. 13, the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee unanimously recommended Spark's Luxturna in a vote of 16 to 0.
-
Backed by Atlas Venture, Lightstone Ventures and OrbiMed, Gemini has emerged with $42.5M in Series A funding and a focus on rare genetic diseases.
-
Cydan snagged $34M to fund its rare disease pipeline and also tapped two new members of its executive leadership team.
-
The money will be to provide patient and caregiver support, funding education and investing in the community.
-
Ablynx Announces Launch Of Proposed Global Offering
10/17/2017
Ablynx intends to offer and sell, subject to market and other conditions, approximately $175 million of its ordinary shares in a global offering.
-
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock
10/17/2017
The gross offering size for this offering is expected to be approximately $80 million.
-
Immunovaccine Receives an Extension to the Maturity Date of its $5M Loan Until 2020
10/17/2017
The new maturity date is now August 9, 2020.
-
Precision Medicine Meets Single-Cell DNA Analysis With Mission Bio
10/17/2017
Mission Bio, Inc., a pioneer in single-cell DNA analysis, today announced it has secured $10 million in Series A funding. Silicon Valley venture capital firm Mayfield Fund led the round.
-
Syndax Announces $25 Million Registered Direct Offering of Common Stock
10/17/2017
Syndax today announced that it has agreed to sell 2,021,018 shares of its common stock to BVF in a registered direct offering.
-
Einstein Researchers Share $9M Grant to Find Anti-Aging Therapies
10/17/2017
Scientists now believe that the Fountain of Youth flows from our genes, or at least from the genes of people who live healthy lives to age 100 or later.
-
Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes
10/17/2017
Valeant announced today the results to date of the pending cash tender offers by Valeant and Valeant Pharmaceuticals International to purchase up to $1,000,000,000 aggregate principal amount of their respective outstanding notes.
-
CytRx Corp. Announces Outcome of Nasdaq Hearing
10/17/2017
CytRx Corp. today announced that Nasdaq has granted the Company's request for a continued listing pending the results of a stockholder vote on or before October 30, 2017.
-
The cash will support continued global adoption of its esophageal temperature management device.
-
Intrexon today announced that it has entered into a Preferred Stock Equity Facility with an affiliate of Third Security.
-
ReWalk Robotics Launches Public Offering of Ordinary Shares
10/17/2017
ReWalk announced the commencement of its underwritten public offering of ordinary shares of the Company.
-
Akonni Biosystems Awarded Grant to Evaluate the TruDiagnosis Molecular Diagnostics Platform for Use in Low Resource Settings
10/17/2017
Akonni Biosystems today announced it was chosen as a recipient for a challenge grant from the Bill & Melinda Gates Foundation.
-
The new venture capital fund with a focus on early-stage companies is making waves in the biotech world.
-
Ramaswamy's Myovant Sciences Scores $140M
10/16/2017
Myovant Sciences has secured up to $140 million in flexible financing commitments from NovaQuest Capital Management and Hercules Capital. -
Landmark Roche patents that helped launch the modern biotechnology era end next year, extinguishing a source of billions of dollars in income.
-
Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies
10/16/2017
Nine global foundations collaborate to grant $13.85 million for the continued advancement of lead Sanfilippo gene therapy programs.